Puerarin is a flavonoid that mainly exists in the TCM Pueraria montana var. Lobata (Willd.) Maesen and S.M.Almeida ex Sanjappa and Predeep (Fabaceae; Puerariae Lobatae Radix), which has been used to treat DM in China since the 1990s (Zhou et al., 2014). According to research, puerarin plays an essential role in antioxidation. For example, it has been reported that oral puerarin (18, 45 mg/kg/day) can significantly reduce serum H₂O₂ and NO levels, inhibit the expression of NOX2 and NOX4, and regulate NF-κB in STZ-induced diabetic rats (Li et al., 2016). Moreover, most studies point out that puerarin can achieve its antioxidant function by changing the level of enzymes related to the oxidation process. Specifically, first, puerarin can protect islets from oxidative stress induced by hydrogen peroxide by increasing peroxidase and SOD (Xie and Du, 2011). Second, studies have shown that treatment with puerarin (100 μM) can upregulate the mRNA levels of endogenous antioxidant enzymes in 3T3-L1 preadipocytes so that they increase glucose-6-phosphate dehydrogenase (G6PDH), GR and hydrogen peroxide enzyme expression (Lee O.-H. et al., 2010). Third, puerarin (200 mg/kg) can improve lead-induced liver injury and hyperlipidemia by downregulating ROS production, upregulating antioxidant enzyme activity, and reducing liver lipid synthesis by upregulating metabolic gene expression in lead-induced rats (Liu et al., 2011). Some reports have demonstrated that puerarin possesses anti-inflammatory activity. Puerarin (100 mg/kg/day) can reduce liver damage by inhibiting NF-κB-driven liver inflammation and the TGF-β/smad signaling pathway in HFD-induced diabetic rats (Hou et al., 2018). Elevated blood sugar is an essential factor in diabetes, and puerarin can effectively regulate blood sugar; for example, intravenous puerarin (15 mg/kg) can lower blood glucose levels in STZ-induced diabetic rats (Hsu et al., 2003). Puerarin also significantly enhances glucose uptake by insulin-sensitive cells and reduces blood glucose levels (Zhou et al., 2014). At the same time, it is reported that puerarin can regulate lipid metabolism. In the adipose tissue of T2DM rats, puerarin (40, 80, and 160 mg/kg) significantly blocked the mRNA expression of the adipose differentiation-related protein (ADRP) gene (Sun et al., 2008).

Furthermore, studies have pointed out that puerarin can promote glucose uptake of adipocytes by promoting PPARγ expression and enhancing the differentiation of preadipocytes (Xu et al., 2005). Puerarin affects pancreatic islet cells to influence the development of DM. In high-fat-diet (HFD) induced and db/db diabetic mice, puerarin (150 mg/kg) increases pancreatic β-cell mass and proliferation by promoting β-cell survival and inhibiting apoptosis, and increasing insulin secretion via activation of GLP-1R signaling (Yang et al., 2016). Different dosages of puerarin (20, 40, and 80 mg/kg) administration effectively reduce pancreatic tissue damage and upregulate intrapancreatic protein levels of insulin receptor substrate-1 (IRS-1) and insulin-like growth factor-1 (IGF-1) in STZ-induced diabetic mice (Wu et al., 2013). In addition, puerarin can increase the activity of antioxidative stress-related enzymes (such as CAT and SOD) and scavenge ROS to protect pancreatic islets and β-cells (Chen X. et al., 2018).

Quercetin is a flavonoid widely distributed in TCM, including Panax notoginseng (Burkill) F.H.Chen (Araliaceae; Notoginseng Radix et Rhizoma), Tussilago farfara L. (Asteraceae; Farfarae Flos), Platycladus orientalis (L.) Franco (Cupressaceae; Platycladi Cacumen), etc., has been shown to play a curative effect in DM. Quercetin has two antioxidant groups in the quercetin molecule, namely the catechol group in the B ring and the OH group at the third position of the A ring, which exerts its antioxidant activity by inhibiting free radicals and increasing oxidase activity (D'Andrea, 2015). Quercetin can prevent the formation of free radicals by preventing the spread of lipid peroxidation and increasing glutathione levels. In the STZ-induced broiler model, quercetin (0.2, 0.4, and 0.6 g/kg) can regulate glucose metabolism and reduce oxidative damage by increasing the activity of antioxidant enzymes, reducing the levels of MDA and NO, and activating the expression of genes related to PI3K/PKB (Ying et al., 2020). Studies have shown that quercetin (20 μmol/L) can protect β-cells from oxidative damage and promote insulin secretion through the ERK1/2 pathway in INS-1 cells (Youl et al., 2010). In addition, quercetin can protect cells suffering from oxidative stress by preventing Ca²⁺-dependent cell death. Quercetin has proven to be a powerful anti-inflammatory weapon. Although the anti-inflammatory mechanism of quercetin is still unclear, researchers have carried out many explorations. Its anti-inflammatory mechanism has increased antioxidant activity, modulated NF-κB, and reduced pro-inflammatory enzyme activity and cytokine levels (Chen et al., 2016). Studies have demonstrated that quercetin (10, 20 μM) can inhibit the production of COX-2 and PGE₂ by targeting PI3K in RLE cells (Lee K. M. et al., 2010). In primary orbital fibroblasts and tissue culture, quercetin (100 μM) can block the production of proinflammatory cytokines (Yoon et al., 2012). In addition, quercetin plays a vital role in glucose and lipid metabolism. Quercetin (0, 10, 50, and 100 μM) can block adipogenesis by stimulating the mitogen-activated protein kinase (MAPK) signaling pathway and induce mature adipocyte apoptosis by controlling the ERK and JNK pathways in 3T3-L1 preadipocytes (Ahn et al., 2008; Chen et al., 2016). Quercetin is a flavonoid glycoside, which becomes quercetin after hydrolysis. Quercitrin also has an antidiabetic effect similar to that of quercitrin. In STZ-induced diabetic rats, quercitrin (30 mg/kg) orally administered for 30 days significantly decreased fasting blood glucose, increased insulin levels, and improved the antioxidant status of diabetic rats by reducing lipid peroxidation products and increasing antioxidants (Babujanarthanam et al., 2011). These results suggest that quercetin has antioxidant effects in STZ-induced experimental DM. In another experiment of STZ-induced diabetic rats, oral administration of quercitrin (30 mg/kg) for 30 days caused decreased blood glucose, increased insulin levels, and restored glycogen content and carbohydrate metabolic enzyme activities (Babujanarthanam et al., 2010). This result suggests that quercetin positively impacted glucose metabolism in diabetic rats.

Luteolin, a natural flavonoid, is beneficial in treating DM, found in TCM such as Lonicera japonica Thunb. (Caprifoliaceae; Lonicerae Japonicae Flos), Perilla frutescens (L.) Britton (Lamiaceae; Perillae Folium), etc. It is demonstrated that luteolin has an antioxidant effect through the NOS/NO pathway and Nrf2-related antioxidative signaling pathway. The NOS/NO pathway plays a vital role in oxidative stress. Luteolin (10, 50, and 100 mg/kg) decreased ROS level and OH− • formation and increased level of NO and NOS, and SOD activity in rat aorta of STZ-induced diabetic rats, which proved that luteolin reduced oxidative stress by upregulating activity in NOS–NO pathway (Qian et al., 2010). In STZ-induced diabetic rats, luteolin (50 mg/kg) reduced oxidative stress by elevating the eNOS expression, enhancing MnSOD, and suppressing mPTP downstream to protect the diabetic heart after ischemia/reperfusion (Yang et al., 2015). Moreover, the nuclear factor erythroid 2-related factor 2 (Nrf2) is critical in ameliorating oxidative stress. Luteolin (100 mg/kg) elevated the levels of antioxidant enzymes (e.g., SOD, GSH), reduced MDA, and enhanced nuclear Nrf2 and the Nrf2-related antioxidative signaling pathway attenuated cardiac ischemia/reperfusion injury in STZ-induced diabetic rats (Chen Y. et al., 2017). Luteolin (100 mg/kg) ameliorated the expression of antioxidant genes regulated by Nrf2, reduced MDA, and blocked sestrin2 transcription in the diabetic I/R hearts, suggesting that Nrf2 and sestrin2 stimulated antioxidative effects in STZ-induced rats (Xiao et al., 2019; Zhou et al., 2021). The anti-inflammatory effect of luteolin is also crucial to the treatment of DM by inhibiting the expression of inflammatory cytokines, NF-κB and TNF-α. In STZ-induced diabetic rats, luteolin (25, 50, and 100 mg/kg) suppressed IL-1β, vascular endothelial growth factor, NF-κB mRNA, and protein expression (Gu et al., 2018). Treatment with luteolin (50, 100 mg/kg) decreased the IL-1β mRNA and TNF-α mRNA expression in the hippocampus, thereby ameliorating inflammation, suggesting an anti-inflammatory effect of luteolin (Gu et al., 2018). Glucose and lipid metabolism are closely related to DM, and luteolin can modulate glucose and lipid metabolism by upregulating LXRα expression and downregulating of FAS and SREBP-1c expression. LXRα is a nuclear receptor that affects lipid and cholesterol metabolism (Christopherson et al., 2009). Luteolin (0.005%, w/w) suppressed hepatic lipogenesis and lipid absorption and simultaneously increased adipocyte PPARγ protein expression to control lipid metabolism in HFD-induced mice (Kwon et al., 2015). In addition, luteolin ameliorated IR through TNF-α, SREBP1 expression, and PI3K signaling. TNF-α is one of the proinflammatory cytokines that can directly affect beta-cell function. Both in vivo and in vitro studies indicated that luteolin attenuated IR through the activation of AMPKα1 signaling in HFD-induced mice and RAW 264.7 cells (Zhang et al., 2016). Decreased expression of Irs2 can lead to IR, while Irs2 is negatively feedback-regulated by SREBP1, and luteolin improves hepatic insulin sensitivity by inhibiting SREBP1 expression in HFD-induced mice (Kwon et al., 2015).

Myricetin, a natural flavonoid, is abundantly found in plants which can be extracted in Myrica rubra (Lour.) Siebold and Zucc. (Myricaceae). Myricetin possesses antidiabetic properties, such as anti-antioxidant, anti-inflammatory, regulation of glucose and lipid metabolism, and protection of islets. Myricetin can reduce the oxidative damage of diabetes-related bone diseases. In 2-deoxy-D-ribose-induced osteoblasts MC3T3-E1 cells, myricetin (10⁻⁹–10^–5 M) increased the survival rate of cells, reduce the production of MDA protein carbonyl, and advanced the oxidation of protein (Lee and Choi, 2008). Myricetin also blocks oxidative stress by increasing the activity of antioxidant enzymes (SOD, CAT, etc.) (Semwal et al., 2016). For example, myricetin (3 mg/kg) significantly increased GSH levels and CAT activity in kidney tissues (Hassana et al., 2017). In isolated rat liver nuclei, myricetin was found to have pro-oxidant properties, and it can induce nuclear DNA degradation that coincides with lipid peroxidation, which can be enhanced by the action of copper (II) and iron (III) (Sahu and Gray, 1993; Semwal et al., 2016). Myricetin was found to have good anti-inflammatory activity. Studies have pointed out that oxidative stress activates multiple inflammatory mediators associated with several chronic diseases, and it is known from the preceding that myricetin can block oxidative stress by increasing the activity of antioxidant enzymes (Song et al., 2021). In addition, studies revealed that myricetin possessed potential effects on inflammatory osteolysis through the regulation of RANKL-related signals (Wang et al., 2018). Glucagon-like peptide-1 (GLP-1) is an effective potential target for treating type 2 diabetes, stimulating insulin secretion, and regulating blood sugar levels (Li et al., 2017). Myricetin can act as a GLP-1 receptor (GLP-1R) agonist, and studies verified that long-term oral administration of myricetin could regulate glucose metabolism (Li et al., 2017). α-Amylase (α-Amy) and α-Glu are two enzymes involved in starch hydrolysis, which can promote an increase in blood sugar. Studies have shown that myricetin (0.5, 1 μg/ml) inhibits α-Amy and α-Glu activity, thereby decreasing blood sugar levels (Meng et al., 2016). CDK5 and ERS are closely related to β-cell exhaustion in T2DM. Studies have shown that myricetin can prevent induced pancreatic β-cell dysfunction by inhibiting CDK5-p66Shc signaling and ERS (Song et al., 2021).

Kaempferol is a natural product of flavonoids with antidiabetic activities in Chinese medicinal botanical drugs, such as Kaempferia galanga L. (Zingiberaceae; Kaempferiae Rhizoma). Kaempferol can increase the expression or activity of antioxidant enzymes (e.g., SOD, CAT, and heme oxygenase-1) and inhibit the activity of ROS-producing enzymes (e.g., xanthine oxidase) to express its antioxidant effect. Kaempferol (10 μM) inhibited dRib-induced intracellular ROS, apoptosis, and lipid peroxidation, and kaempferol was effective in scavenging Fenton-generated hydroxyl radicals and peroxynitrite (Lee Y. J. et al., 2010; Calderon-Montano et al., 2011). These results suggest that kaempferol protects HIT-T15 cells from dRib-induced oxidative damage. Kaempferol has a specific anti-inflammatory effect through variety of mechanisms. The activation of NF-κB and TNF-α can induce inflammation, and kaempferol exhibits anti-inflammatory activity by inhibiting the activity of NF-κB and TNF-α (Calderon-Montano et al., 2011). AP-1 (activator protein 1) is a transcriptional regulator composed of members of the Fos and Jun family involved in inflammation, and kaempferol (50 μM) has been shown to inhibit the activation of AP-1 in PC3 cells (Gopalakrishnan et al., 2006). Cyclooxygenase (COX), lipoxygenase (LOX), and inducible nitric oxide synthase (iNOS) are essential enzymes of eicosanoid synthesis in inflammation, and kaempferol exerts anti-inflammatory by inhibiting the activity of these enzymes (e.g., COX, LOX, and iNOS) (Calderon-Montano et al., 2011). Furthermore, kaempferol can inhibit key mediators of oxidative stress-induced inflammation, such as NO and iNOS (Alam et al., 2020). In vivo study, kaempferol (50, 150 mg/kg) reduced liver inflammation by downregulating IKK and inhibiting NF-κB pathway activation (Luo et al., 2015). Kaempferol showed significant modulation of glucose and lipid metabolism. Kaempferol stimulates glycogen synthesis in the soleus muscle through PI3K, GSK-3, MAPK, and PP1 (Cazarolli et al., 2009). In 3T3-L1 adipocytes, kaempferol (5, 10, 20, and 50 μM) may improve insulin-stimulated glucose uptake as ligands of PPARγ (Fang et al., 2008). Kaempferol may be an anti-diabetic compound protecting pancreatic beta-cell survival and function. Kaempferol (10 μM) protects β-cells by inducing cAMP generation and upregulating the protein expression of Akt and Bcl-2 (Zhang and Liu, 2011).

Hesperidin is a flavonoid mainly found in citrus plants such as the Chinese medicine Citrus × aurantium L. (Rutaceae; Citri Reticulatae Pericarpium), which exerts beneficial biological activities in treating DM. Hesperidin acts as an antioxidant by preventing the production of ROS. In a rat exhaustive exercise model, hesperidin (200 mg/kg) can prevent ROS production and avoid attenuating the activity of CAT and SOD in the chest and spleen (Estruel-Amades et al., 2019). Under high levels of glucose-induced oxidative stress and apoptosis in retinal ganglion cells (RGCs), hesperidin (12.5, 25, and 50 μmol/L) inhibited cell apoptosis by reducing the levels of Caspase-9, Caspase-3, and Bax/Bcl-2, and hesperidin also elevated the activity of enzymes related to antioxidation and recovered glutathione levels (Liu et al., 2017). Besides, hesperidin has anti-inflammatory activity. Hesperidin can regulate the NF-κB inflammatory signaling pathway by mediating the AMPK and PPAR pathways, thereby reducing inflammation and apoptosis (Xiong et al., 2019). In HFD-induced C57BL/6J mice, hesperidin (100 mg/kg) manifested systematic inflammation by suppressing the elevation of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and C-reactive protein (hs-CRP) (Ferreira et al., 2016). Hesperidin can treat DM by regulating glucose and lipid metabolism. Hesperidin (10, 50 μM) inhibited amylose and amylopectin digestion and significantly reduced glucose-6-phosphatase activity in HepG2 cells (Shen et al., 2012). Furthermore, hesperidin (40, 80, 120, 160, and 200 μM) blocked the enzyme entrance channel, restrained the combination between substrates and enzyme active sites, and inhibited hepatic gluconeogenesis by preventing the production of pyruvate, α-ketoglutarate, and oxaloacetate (Zareei et al., 2017). PPAR-c is a nuclear protein transcription factor closely related to lipid and glucose metabolism. In a vitro experiment, hesperidin increased glucose uptake and PPAR-γ activity or PPAR-γ mRNA expression in C2C12 myotubes. In contrast, in vivo experiment, hesperidin improved the impaired fasting glucose level and glucose tolerance (Shin et al., 2013). Hesperidin can regulate lipid metabolism by regulating adipokines, cytokines, and lipogenesis-related genes to some extent. In addition, hesperidin can affect IR and improve glucose homeostasis and insulin sensitivity (Xiong et al., 2019).

Baicalein is one of the flavonoids with the highest content in the TCM Scutellaria baicalensis Georgi (Lamiaceae; Scutellariae Radix). Baicalein can inhibit inflammation and IR by activating AMPK in the treatment of diabetic mice. In HFD-induced mice treated with 400 mg/kg of 0.5% baicalein, a study showed that the activation of AMPK can downregulate insulin receptor substrate 1 (IRS-1) and Akt through phosphorylation and can also reduce SREBP-1c and FAS gene transcription and upregulate PPAR-α gene expression and fat target genes to inhibit cholesterol and fatty acid synthesis, thereby further achieving the purpose of treating DM (Pu et al., 2012). Baicalein (80 mg/kg) shuts down lipid metabolism by downregulating the related genes SREBP-1c and FAS, critical enzymes for cholesterol and fatty acid synthesis in HFD-fed rats, and even reduces serum cholesterol, FAA, and TNF-α by activating ACC and AMPK during their phosphorylation (Guo et al., 2009). In addition, baicalein can also delay glucose absorption by inhibiting digestive enzymes such as α-Amy and α-Glu. Therefore, baicalein can be an auxiliary drug for diabetic dietary treatment (Zhang et al., 2017). Studies have pointed out that baicalein can inhibit pancreatic β-cell damage by inhibiting the expression of 12-lipoxygenase (Deschamps et al., 2006). Another study showed that baicalein could also enhance mitochondrial function in β-cells through a cAMP-dependent pathway, thereby increasing the vitality and function of β-cells (Dinda et al., 2017).

Apigenin is a flavonoid widely present in nature, especially in vegetables, such as Apium graveolens var. dulce (Mill.) Pers. (Umbelliferae), Petroselinum crispum (Mill.) Fuss (Umbelliferae), and Matricaria chamomilla L. (Asteraceae). According to research, apigenin shows bioactivity in diabetes, and apigenin may treat DM through different mechanisms. Apigenin exerts its antioxidant effect mainly by enhancing antioxidants and neutralizing active oxygen. For example, apigenin can prevent DM and complications by interacting with and neutralizing ROS in cells (Wang et al., 2014). In alloxan-treated mice, apigenin can protect the liver by enhancing the activity of antioxidants (such as CAT) with the administration of 0.78 mg/kg of apigenin for 10 consecutive days (Panda and Kar, 2007). Besides, apigenin can regulate lipid peroxidation in alloxan-treated mice, where the group with reduced blood lipids and blood sugar has increased SOD activity and glucose tolerance compared with the control group (Panda and Kar, 2007). Apigenin has a specific anti-inflammatory role through different pathways, including p38/MAPK and PI3K/Akt. It can also prevent IKB degradation and nuclear translocation of NF-κB and reduce COX-2 activity at the same time (Lee J.-H. et al., 2007). Other studies have shown that apigenin can protect β-cell function by inhibiting inflammatory signaling pathways (Bai et al., 2019).

Catalpol is a terpenoid extracted from the TCM Rehmannia glutinosa (Gaertn.) DC. (Orobanchaceae; Rehmanniae Radix), which has been demonstrated to have antidiabetic properties. Catalpol plays a vital role in oxidative stress. In HFD/STZ-induced mice, catalpol (100, 200 mg/kg) increased GSH and SOD, reduced MDA levels, and decreased NOX4 protein overexpression (Yan et al., 2018). In DM mice and GC-2 cells, catalpol prevented ROS production by inhibiting the expression of RAGE, Nox4, and NF-κB p65, thereby reducing the oxidative stress induced by AGEs (Jiao et al., 2020). In addition, catalpol can reduce oxidative stress by increasing the formation of mitochondria. Studies have pointed out that catalpol (50, 100, 200 mg/kg) can improve the function of hepatic mitochondria by activating Mfn1 and downregulating Fis one and Drop one in HFD/STZ-induced mice (Xu et al., 2015; Bhattamisra et al., 2021). Studies have indicated that catalpol reduced inflammation by suppressing ROS production, pro-inflammatory factors, and the NF-κB pathway. In HFD-induced mice, catalpol (100 mg/kg) exerted anti-inflammatory effects by inhibiting M1 proinflammatory factors and increasing M2 anti-inflammatory factors in adipose tissue, and catalpol ameliorated IR and inflammation by suppressing the JNK and NF-kB pathways (Zhou et al., 2015). In THP-1 cells, catalpol (100, 300, and 500 μM) inhibited the expression of proinflammatory mediators (e.g., MCP-1, TNF-α, iNOS), phosphorylation of MAPK, production of ROS, degradation of IκBα and the nuclear localization of NF-κB (Choi et al., 2013). Glucose and lipid metabolism are also important in DM treatment. Catalpol can prevent gluconeogenesis by activating AMPK and inhibiting the expression of PEPCK and G6Pase proteins (Bhattamisra et al., 2021). In HepG2 cells, catalpol (20, 40, and 80 μM) activated the PI3K/AKT pathway to promote glycogen production and inhibit gluconeogenesis (Yan et al., 2018). Catalpol (25, 50, 100, and 200 mg/kg) can remarkably ameliorate gene expression, especially SOCS3, to modulate glucose metabolism in db/db mice (Liu et al., 2018). Furthermore, catalpol benefits IR and insulin sensitivity. Both in vivo and in vitro studies suggest catalpol can ameliorate IR; for example, catalpol may suppress IR by inhibiting the overexpression of NOX4 and activating AMPK in glucosamine-induced HepG2 cells (Yan et al., 2018). In addition, catalpol (100, 200 mg/kg) can improve insulin sensitivity via the insulin-related signaling pathway and AMPK/SIRT1/PGC-1α/PPAR-γ activation in STZ/HFD-induced diabetic mice (Yap et al., 2020).

Oleanolic acid is a terpenoid widely present in plants, which can be extracted from the TCM Ligustrum lucidum W.T.Aiton (Oleaceae; Ligustri Lucidi Fructus). It has been demonstrated that oleanolic acid possesses antidiabetic effects in treating DM. Oleanolic acid may increase the activities of antioxidant enzymes to exert antioxidant effects. In alloxan-induced diabetic rats, oleanolic acid (60, 100 mg/kg) reduced the MDA level and increased the activities of SOD and GSH-Px, which indicated that oleanolic acid possessed antioxidant effects (Gao et al., 2009). Furthermore, studies suggest that oleanolic acid elevated antioxidant enzymes (e.g., SOD, CAT, and GSH-Px) via the transcription factor Nrf2 (Castellano et al., 2013). Oleanolic acid also has anti-inflammatory effects. In vivo and in vitro studies indicated that oleanolic acid possesses anti-inflammatory properties, mediated by decreasing the NF-κB expression and TNF-α generation (Lee et al., 2013). In db/db mice, oleanolic acid (20 mg/kg) ameliorates the inflammatory condition by downregulating of IL-1 β, IL-6, and TNF-α in the circulation, which improves hepatic IR (Wang et al., 2013). Oleanolic acid has a specific effect on regulating glucose and lipid metabolism. The experiments showed that oleanolic acid could control blood sugar by inhibiting α-Glu (Ding et al., 2018). PPARs are a family of nuclear transcription factors of the sterol receptor superfamily, which can regulate lipid and glucose metabolism (Berger et al., 2005). In vitro studies, oleanolic acid stimulated GLUT-4 translocation in C2C12 myoblasts, inhibited lipid accumulation in 3T3-L1 adipocytes, and affected PPARγ/α. These results suggested that oleanolic acid may have an antihyperglycemic effect (Loza-Rodríguez et al., 2020). Subsequently, oleanolic acid (25 mg/kg) improved IR through the IRS-1/PI3K/Ak pathway (Li et al., 2014). In addition, oleanolic acid (50 mg/kg) could ameliorate IR by the PPARγ signaling through the upregulation of hepatocyte nuclear factor 1b (HNF1b) and in aroclor 1254-induced mice (Su et al., 2018).

Crocin, an uncommon terpenoid, is one of the main components of the TCM Crocus sativus L. (Iridaceae; Croci Stigma), which can treat DM and its complications through its bioactivities. MDA and ER are closely related to cellular oxidative stress. Experiments indicated that crocin can exert its antioxidant effect by scavenging free radicals, reducing MDA levels, increasing GPx and SOD activities, and regulating mRNA expression of ER stressors (Korani et al., 2019). Crocin (5, 10, and 20 mg/kg) decreased MDA levels and increased GSH-px and SOD activities in the reperfusion-induced oxidative/nitrative injury mice, thereby expressing its antioxidant effect (Zheng et al., 2007). Meanwhile, crocin has an anti-inflammatory effect. Crocin (10, 20, and 30 mg/kg) inhibited the activation of inflammatory signaling by suppressing the mRNA expression of proinflammatory cytokines (e.g., TNF-α, IL-6) in STZ-induced diabetic rats (Samarghandian et al., 2016).

Loganin, a common terpenoid, is one of the main components of Cornus officinalis Siebold and Zucc. (Cornaceae; Corni Fructus) has bioactivity in DM and its complications. The experiment of RSC96 Schwann cells pretreated with loganin (0.1, 1, 10, 25, and 50 µM) indicated that the antioxidant effects of loganin prevented the apoptosis of RSC96 Schwann cells by inhibiting the production of ROS and the activation of NLRP3 inflammasomes, thereby playing a role in neuropathy caused by DM (Cheng et al., 2020).

Berberine is a quaternary ammonium alkaloid that is mainly extracted from the TCM Coptis chinensis Franch. (Ranunculaceae; Coptidis Rhizoma), which has various biological mechanisms in treating DM. Studies have demonstrated that berberine has antioxidant effects through different mechanisms. In STZ/HFD-induced diabetic rats, berberine (75, 150, and 300 mg/kg) decreased MDA levels and increased the activities of antioxidant enzymes (e.g., SOD, GSH, GSH-Px, CAT) in rat liver cells, thereby overcoming oxidative stress (Zhou and Zhou, 2011). Nrf2 can activate the expression of antioxidant enzymes (e.g., SOD, and GSH), and studies have shown that berberine (0.1–10 nM) can activate Nrf2 nuclear translocation and protect against oxidative damage via a PI3K/Akt-dependent pathway in NSC34 neuronal cells (Hsu et al., 2012). Proinflammatory cytokines (e.g., TNF-α, IL-6, iNOS, and COX2) are closely related to DM, and NF-κB plays an important role in producing proinflammatory cytokines. Berberine can inhibit NF-κB through the suppression of phosphorylation of IκB kinase-β (IKK-β) and RhoA/ROCK signaling pathways (Chang et al., 2015). Berberine exerts anti-inflammatory effects via the AMPK and Nrf2 pathways in vivo and in vitro. In RAW264.7 cells (treated with 5 μmol/L berberine) and LPS-induced mice (treated with 10 mg/kg berberine), the expression of inflammatory genes (e.g., iNOS, COX2, and IL-6) and the generation of NO and ROS were attenuated, but Nrf2-targeted antioxidative genes increased (Mo et al., 2014). In STZ/HFD-induced diabetic rats, berberine (380 mg/kg) mainly regulated glucose and lipid metabolism by reducing the expression of nuclear transcription factors (e.g., FoxO1, SREBP1, and ChREBP) in the liver (Xia et al., 2011). Hepatic nuclear factor 4α (HNF-4α) is a factor of the hepatic nuclear family that can inhibit gluconeogenesis. Berberine (1, 3, 10, and 30 μmol/L) can inhibit hepatic gluconeogenesis by upregulating the mRNA and protein expression of HNF-4α in rat pancreatic islets (Wang et al., 2008). PPARs (peroxisome proliferator-activated receptors) play an important role in regulating target gene expression related to glucose and lipid metabolism, including PPARγ, PPARα, and PPARδ (Berger and Moller, 2002). Berberine can upregulate hepatic low-density lipoprotein receptor (LDLR) by activating the c-Jun N-terminal kinase (JNK) pathway in HepG2 and HEK-293 cells (Lee S. et al., 2007). Studies have identified that berberine can affect insulin functions and β-cells. The insulin receptor (InsR) is a cell membrane glycoprotein essential in IR. In human liver cells and rat models, berberine increased the InsR mRNA and protein expression to reduce IR (Kong et al., 2009). Moreover, another study pointed out that berberine (100 mg/kg) affected the phosphorylation of InsR and its insulin receptor substrate-1 (IRS-1) in db/db mice, which ultimately led to reduction in IR (Chen et al., 2010). In H9c2 cells, the study indicated that berberine (3.125–100 μmol/L) improved IR at least via the stimulation of AMPK activity, and berberine also increased glucose consumption and glucose uptake (Chang et al., 2013). Berberine (5 mg/kg) improved insulin-sensitizing and lipid-lowering properties in db/db mice, and berberine activated the AMPK activity in 3T3-L1 cells and stimulated GLUT4 translocation in L6 myotubes (Lee et al., 2006). Moreover, berberine (187.5 mg/kg) enabled the upregulation of insulin receptor substrate 2 mRNA in nonalcoholic fatty liver disease (NAFLD) rat liver (Xing et al., 2011). Glucagon-like peptide-1 (GLP-1) is an important incretin that promotes insulin secretion and inhibits glucagon secretion. GLP-1 receptors play an important role in the survival of pancreatic islet cells. Berberine (120 mg/kg) may significantly stimulate GLP-1 secretion to promote insulin secretion and improve β-cell function in STZ-induced diabetic rats (Yu et al., 2010).

Matrine is an alkaloid extracted in the Chinese medicine Sophora flavescens Aiton (Fabaceae; Sophorae Flavescentis Radix), which has beneficial effects on DM treatment. Studies have pointed out that marine exerts antioxidant effects by reducing ROS production via the PI3K/Akt pathway. Matrine (5, 20, and 80 μmol/L) could elevate NO levels and eNOS activity and downregulate intracellular ROS production in ox-LDL-induced HUVEC injury, mediated through the PI3K/Akt pathway (Zhang et al., 2019). Furthermore, matrine could block inflammatory factors to express their anti-inflammatory effect. Matrine (0.5, 2.5, and 10 mg/kg) reduced TNF-α, IL-6, and elevated IL-10 levels, demonstrating that marine had anti-inflammatory effects by regulating inflammatory cytokines in HFD-induced mice (Zhang et al., 2019). In addition, the matrine significantly affects glucose and lipid metabolism through ER stress and the PK2/PCRs pathway. In STZ/HFD-induced mice, matrine (40 mg/kg) reduced FBG, improved glucose tolerance, suppressed lipid production while preventing ER stress-related protein overexpression, and increased PK2, PKR1, and PKR2 expression. These results indicated that matrine ameliorated glucose and lipid metabolism by suppressing ER stress and regulating the PK2/PCRs pathway (Zhang et al., 2022). GLP-1 is a hormone secreted by the intestines that can regulate glucose metabolism by stimulating insulin secretion, and studies have pointed out that matrine can stimulate GLP-1 secretion and improve IR. A dose of matrine treatment (10 mg/kg) elevated GLP-1 protein expression and plasma GLP-1 levels stimulated by CaSR, thus improving glucose homeostasis in STZ/HFD-induced mice (Guo et al., 2021).

Betaine, a quaternary ammonium alkaloid, is widely found in plants such as the Chinese medicine Lycium barbarum L. (Solanaceae; Lycii Fructus), which can treat DM through its activities. Studies have pointed out that the primary antioxidant mechanism of betaine may be achieved by improving the metabolism of SAA, and reducing the endoplasmic reticulum and oxidative stress in db/db mice (Jung G. Y. et al., 2013). In addition, researchers have found that betaine has protective effects attributed to antioxidant defense by ameliorating impaired sulfur amino acid metabolism in alcoholic liver injury (Jung Y. S. et al., 2013). Betaine is a valuable agent for suppressing inflammation by inhibiting the NF-κB and IL-1β. Studies have indicated that betaine (30, 60, and 120 mg/kg) inhibits NF-κB activation via NIK/IKK and MAPKs to suppress the production of proinflammatory cytokines in old SD rats (Go et al., 2005). Additionally, betaine can inhibit the NLRP3 inflammasome by enhancing IRS activity to activate PKB/Akt pathway (Zhao et al., 2018). In addition, betaine exerts anti-inflammatory effects by restoring energy metabolism and reducing endoplasmic reticulum stress and apoptosis. In high-sucrose diet-induced mice, betaine (1% wt/vol) regulated glucose and lipid metabolism by activating AMPK and other lipid metabolism-related factors (Song et al., 2007). Both in vivo and in vitro studies, betaine improved IR by increasing IRS1 phosphorylation and ameliorating downstream pathways related to gluconeogenesis and glycogen synthesis via the PI3K/Akt signaling pathway (Kathirvel et al., 2010).

Curcumin, a polyphenolic compound, possesses different mechanisms in treating DM, which can be extracted from the traditional Chinese Curcuma longa L. (Zingiberaceae; Curcumae Longae Rhizoma). According to research, curcumin acts as an antioxidant agent by enhancing the activity of antioxidant enzymes and scavenging radicals. Despite the presence or absence of bone marrow transplantation, curcumin (10 mM) blocked the MDA level and increased the activity of antioxidant enzymes in STZ-induced mice, alleviating lipid peroxidation (El-Azab et al., 2011). In STZ/HFD-induced rats, curcumin (100 mg/kg) attenuated oxidative stress and suppressed diabetic cardiomyopathy apoptosis through Sirt1-Foxo1 and PI3K-Akt signaling pathways (Ren et al., 2020). The anti-inflammatory effect of curcumin contributes to the release of inflammatory cytokines and decreases the NF-κB pathway. NF-κB is a critical transcription factor in the inflammatory response, while AMPK and PPARγ play a role in glucose/lipid metabolism. Curcumin (0.75% v/v) decreased NF-κB expression, activated AMPK expression, and reversed the reduction in PPARγ expression in db/db mice (Jiménez-Flores et al., 2014). Glucose and lipid metabolism are essential in DM, and curcumin can regulate glucose and lipid metabolism through glucose transporters, AMPK, glucose, and lipid metabolism-related enzymes (e.g., GK, ACAT, HMG-CoA reductase). Glucose transporter 2 (GLUT2) is a transmembrane transporter that promotes glucose uptake, and curcumin blocks the translocation of GLUT2. Curcumin (0–30 μM) prevented the membrane translocation of GLUT2 by interrupting the p38 MAPK signaling pathway. It inhibited the gene expression of GLUT2 through the stimulation of PPAγ activity and the decrease in oxidative stress, thus contributing to the elimination of hyperglycemia-stimulated HSC activation, which may have beneficial effects on glucose metabolism (Lin and Chen, 2011). AMPK is a central lipid and glucose metabolism regulator, stimulating muscle glucose uptake. High-dose curcumin (100 mg/kg) reduced the expression and activity of the key enzymes in gluconeogenesis (G6Pase) by activating AMPK in a gestational diabetes mouse model (Lu et al., 2019). Glucose and lipid metabolism-related enzymes also play an important role in glucose and lipid metabolism. In db/db mice, curcumin (0.02%, wt/wt) increased hepatic GK activity, inhibited hepatic gluconeogenic enzyme activities (e.g., G6Pase, PEPCK), and reduced lipid regulating enzyme activities (e.g., HMG- CoA reductase, ACAT) and lipid profiles (e.g., plasma fatty acids, total cholesterol, and TGs) (Seo et al., 2008). Thus, it has been proven that curcumin regulates glycose and lipids. In addition, curcumin could ameliorate IR by downregulating IAPP, GSK-3β, and TNF-α. Islet amyloid polypeptide (IAPP) and GSK-3β are critical peptides in IR. Supplementation with curcumin (180 mg/day) reduced plasma peptide levels of IAPP and GSK-3β in adults with a high risk of type 2 diabetes, thus ameliorating IR (Thota et al., 2020). Curcumin (80 mg/kg) suppressed TNF-α levels and free fatty acid levels in HFD-induced rats and improved insulin sensitivity due to its anti-inflammatory effect by suppressing TNF-α levels (El-Moselhy et al., 2011).

Cinnamaldehyde, a phenylpropanoid compound, has rich activities against DM, which can be extracted from the TCM Neolitsea cassia (L.) Kosterm. (Lauraceae; Cinnamomi Cortex). Studies have pointed out that cinnamaldehyde could have antioxidant effects by elevating antioxidant enzyme activity and activating the Nrf2 pathway. Cinnamaldehyde (20 mg/kg) elevated SOD, GSH, GPx, and CAT, and reduced lipid peroxidation-related TBARS in the pancreatic β-cell injury of STZ-induced diabetic rats. Thus, cinnamaldehyde (5, 10, and 20 mg/kg) protected pancreatic β-cell injury via the elevation of antioxidant enzyme activities (Subash-Babu et al., 2014). In db/db mice, cinnamaldehyde reduced ROS levels, preserved NO production, and elevated Nrf2 and its targeted genes (such as HO-1 and NQO-1), and these results suggested that cinnamaldehyde (0.02% v/v) attenuated oxidative stress through the activation of the Nrf2 pathway (Wang et al., 2020). Cinnamaldehyde also has anti-inflammatory effects by inhibiting inflammatory factors and NF-κB activity. Several studies have demonstrated that cinnamaldehyde regulates glucose/lipid metabolism through GLUT4. RBP4 and GKUT4 are closely related and important factors in glucose and lipid metabolism. Cinnamaldehyde (40 mg/kg) decreased FBG and LDL levels while reducing serum RBP4 levels and elevating GLUT4 protein expression in HFD-induced rats (Zhang et al., 2008). PPARγ is a critical factor in glucose and lipid metabolism, enhancing insulin sensitivity (Feige et al., 2006). Cinnamaldehyde (20 mg/kg) elevated PPARγ gene expression and insulin levels, thus ameliorating IR in FSD/STZ-induced rats (Hosni et al., 2017).

Tan IIA is a quinone compound extracted from the TCM Salvia miltiorrhiza Bunge (Lamiaceae; Salviae miltiorrhizae radix et rhizoma), which possesses bioactivities in treating DM. Tan IIA can protect cells by regulating the level of antioxidant enzymes and reducing the production of ROS (Ansari et al., 2021). In STZ-induced diabetic rats, Tan IIA (2, 4 mg/kg) reduced MDA content and GRP78 and CHOP expression by inducing SOD activity. It also decreased neuronal apoptosis and ameliorated learning and memory by inhibiting ER stress activation (Chen J. et al., 2018). Tan-IIA has been used to treat inflammation in Chinese medicine. Due to the correlation between inflammation and diabetes, Tan-IIA can treat DM through anti-inflammatory effects (Guo et al., 2020). In STZ/HFD-induced diabetic rats, Tan IIA (10 mg/kg) may suppress the levels of inflammatory cytokines (e.g., IL-6, IL-8, and TNF-α), attenuate the level of NF-κB, and increase 5’ adenosine monophosphate-activated protein kinase levels, then overcome the symptoms of type 2 diabetes (Yuan et al., 2018). In STZ-induced diabetic rats, Tan IIA (10 mg/kg) improved renal damage by reducing oxidative stress and inflammation (Chen X. et al., 2017). In addition, studies have pointed out that Tan IIA (0.4 g crude danshen/kg) regulated glucose metabolism by increasing PPARγ and its target genes in HFD-induced diabetic rats (Xie et al., 2015).